“This real-world experience confirms what we see in clinical trials,” says Benjamin Howell, MD, MPH, assistant professor of medicine (general medicine) at Yale School of Medicine (YSM) and lead author of the study. “Medications are shown to improve a range of outcomes like treatment retention, drug use, criminalized behavior, and even employment.”
Methadone and buprenorphine are controlled substances, and are available by prescription only. These medications are used to curb opioid withdrawal symptoms and in ongoing treatment.
“Our access to a unique combination of state-level datasets allowed us to consider multiple treatments in our statistical models and draw meaningful conclusions about people’s risk for overdose,” says Anne C. Black, PhD, associate professor of medicine (general medicine) at YSM and co-author.
The research team also found no statistical differences between inpatient treatment, such as rehabilitation or detox, and receiving no treatment. This means inpatient treatment has no independent effect on subsequent overdoses. The finding, Howell notes, highlights the need for medications to be provided in conjunction with inpatient treatment.
“These medications are considered the gold standard for the treatment of opioid use disorder by the National Institutes of Health and other authoritative bodies, and they are effective because they prevent withdrawal and decrease craving,” says co-author David Fiellin, MD, professor of medicine (general medicine) and of emergency medicine at YSM and of health policy and management at Yale School of Public Health (YSPH).
The study emphasizes the need for public health awareness on the importance of the use of medications to treat patients with opioid use disorder. Researchers hope the data will inform public policy and regulations at the local, state, and federal levels.